Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Treasury Shares: 2019-2025

  • Burning Rock Biotech's Treasury Shares was N/A to -$60.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$60.9 million, marking a year-over-year change of. This contributed to the annual value of $8.7 million for FY2024, which is 6.62% down from last year.
  • Per Burning Rock Biotech's latest filing, its Treasury Shares stood at -$60.9 million for Q2 2025, which was down 802.93% from $8.7 million recorded in Q4 2024.
  • Burning Rock Biotech's 5-year Treasury Shares high stood at $9.3 million for Q4 2023, and its period low was -$60.9 million during Q2 2025.
  • In the last 3 years, Burning Rock Biotech's Treasury Shares had a median value of $179,200 in 2023 and averaged $3.3 million.
  • Per our database at Business Quant, Burning Rock Biotech's Treasury Shares spiked by 3,812.63% in 2020 and then tumbled by 4,794.67% in 2022.
  • Quarterly analysis of 4 years shows Burning Rock Biotech's Treasury Shares stood at $8.5 million in 2022, then rose by 8.65% to $9.3 million in 2023, then dropped by 6.62% to $8.7 million in 2024, then reached -$60.9 million in 2025.
  • Its Treasury Shares stands at -$60.9 million for Q2 2025, versus $8.7 million for Q4 2024 and $9.3 million for Q4 2023.